Aryl hydrocarbon receptor inhibition promotes hematolymphoid development from human pluripotent stem cells.

Citation data:

Blood, ISSN: 1528-0020, Vol: 129, Issue: 26, Page: 3428-3439

Publication Year:
Usage 11
Abstract Views 6
Link-outs 5
Captures 35
Readers 35
Social Media 2
Tweets 2
Citations 3
Citation Indexes 3
Angelos, Mathew G; Ruh, Paige N; Webber, Beau R; Blum, Robert H; Ryan, Caitlin D; Bendzick, Laura; Shim, Seonhui; Yingst, Ashley M; Tufa, Dejene M; Verneris, Michael R; Kaufman, Dan S Show More Hide
American Society of Hematology
Biochemistry, Genetics and Molecular Biology; Immunology and Microbiology; Medicine
Most Recent Tweet View All Tweets
article description
The aryl hydrocarbon receptor (AHR) plays an important physiological role in hematopoiesis. AHR is highly expressed in hematopoietic stem and progenitor cells (HSPCs) and inhibition of AHR results in a marked expansion of human umbilical cord blood-derived HSPCs following cytokine stimulation. It is unknown whether AHR also contributes earlier in human hematopoietic development. To model hematopoiesis, human embryonic stem cells (hESCs) were allowed to differentiate in defined conditions in the presence of the AHR antagonist StemReginin-1 (SR-1) or the AHR agonist 2,3,7,8-tetrachlorodibenzo-dioxin (TCDD). We demonstrate a significant increase in CD34CD31 hematoendothelial cells in SR-1-treated hESCs, as well as a twofold expansion of CD34CD45 hematopoietic progenitor cells. Hematopoietic progenitor cells were also significantly increased by SR-1 as quantified by standard hematopoietic colony-forming assays. Using a clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9)-engineered hESC--tdTomato reporter cell line with deletion, we further demonstrate a marked enhancement of hematopoietic differentiation relative to wild-type hESCs. We also evaluated whether AHR antagonism could promote innate lymphoid cell differentiation from hESCs. SR-1 increased conventional natural killer (cNK) cell differentiation, whereas TCDD treatment blocked cNK development and supported group 3 innate lymphoid cell (ILC3) differentiation. Collectively, these results demonstrate that AHR regulates early human hematolymphoid cell development and may be targeted to enhance production of specific cell populations derived from human pluripotent stem cells.